- Home
- UEC vs MLTX Comparison
UEC vs MLTX Comparison
Compare UEC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEC
- MLTX
- Stock Information
- Founded
- UEC 2003
- MLTX 2021
- Country
- UEC United States
- MLTX Switzerland
- Employees
- UEC N/A
- MLTX N/A
- Industry
- UEC Other Metals and Minerals
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- UEC Basic Materials
- MLTX Health Care
- Exchange
- UEC Nasdaq
- MLTX Nasdaq
- Market Cap
- UEC 2.8B
- MLTX 2.5B
- IPO Year
- UEC N/A
- MLTX N/A
- Fundamental
- Price
- UEC $6.44
- MLTX $43.50
- Analyst Decision
- UEC Strong Buy
- MLTX Strong Buy
- Analyst Count
- UEC 3
- MLTX 8
- Target Price
- UEC $10.08
- MLTX $77.71
- AVG Volume (30 Days)
- UEC 18.3M
- MLTX 676.4K
- Earning Date
- UEC 06-02-2025
- MLTX 08-06-2025
- Dividend Yield
- UEC N/A
- MLTX N/A
- EPS Growth
- UEC N/A
- MLTX N/A
- EPS
- UEC N/A
- MLTX N/A
- Revenue
- UEC $66,837,000.00
- MLTX N/A
- Revenue This Year
- UEC $41,201.79
- MLTX $103.42
- Revenue Next Year
- UEC $25.78
- MLTX N/A
- P/E Ratio
- UEC N/A
- MLTX N/A
- Revenue Growth
- UEC 70.62
- MLTX N/A
- 52 Week Low
- UEC $3.85
- MLTX $31.42
- 52 Week High
- UEC $8.93
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- UEC 56.84
- MLTX 52.69
- Support Level
- UEC $6.46
- MLTX $42.22
- Resistance Level
- UEC $7.15
- MLTX $44.20
- Average True Range (ATR)
- UEC 0.40
- MLTX 2.11
- MACD
- UEC 0.01
- MLTX -0.36
- Stochastic Oscillator
- UEC 53.29
- MLTX 32.18
About UEC Uranium Energy Corp.
Uranium Energy Corp is engaged in uranium mining and related activities. The company is working towards fueling the demand for carbon-free nuclear energy, a key solution to climate change, and energy source for the low-carbon future. The company is advancing its next generation of low-cost, environmentally friendly, in-situ recovery (ISR) mining uranium projects. The company has two extraction-ready ISR hub and spoke platforms in South Texas and Wyoming. UEC also has seven U.S. ISR uranium projects with all of their permits in place, with additional diversified holdings of uranium assets across the U.S., Canada and Paraguay.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.